Aluminum toxicokinetics in peritoneal dialysis patients

Clinical Toxicology

Volumn 49, Issue 7, 2011, Pages 659-663

  Seng Yue, Corinne ^a   Christie, Megan ^b   Lavergne, Valery ^c   Sikaneta, Tabo ^b,d   Taskapan, Hulya ^b   Mardini, Karine ^e   Tam, Paul ^b,d   Ting, Robert ^b,d   Ghannoum, Marc ^e  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Nephrology Associates   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d SCARBOROUGH HOSPITAL   (Canada)

^e Verdun Hospital   (Canada)

Author keywords

Heavy metal; Peritoneal dialysis; Renal failure; Toxicity; Toxicokonetics

Indexed keywords

ALUMINUM;

ADULT; ARTICLE; BLOOD LEVEL; BONE; CONTAMINATION; CREATININE CLEARANCE; DIALYSATE; DISTRIBUTION VOLUME; FEMALE; HALF LIFE TIME; HUMAN; LABORATORY TEST; LIVER; LUNG; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; STEADY STATE; TISSUE DISTRIBUTION; TOXICOKINETICS;

AGED; ALUMINUM; BODY BURDEN; DIALYSIS SOLUTIONS; DRUG CONTAMINATION; FEMALE; HALF-LIFE; HUMANS; KIDNEY DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; ONTARIO; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; QUEBEC; RISK ASSESSMENT; RISK FACTORS; TISSUE DISTRIBUTION;

EID: 80052480096     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2011.602083     Document Type: Article

References (29)

1. Nolte E, Beck E, Winklhofer C, Steinhausen C. Compartmental model for aluminium biokinetics. Hum Exp Toxicol 2001; 20: 111-117. (Pubitemid 32335476)
2. Priest ND. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. J Environ Monit 2004; 6:375-403. (Pubitemid 38716532)
3. Steinhausen C, Kislinger G, Winklhofer C, Beck E, Hohl C, Nolte E, Ittel TH, Alvarez-Bruckmann MJ. Investigation of the aluminium biokinetics in humans: a 26Al tracer study. Food Chem Toxicol 2004; 42:363-371. (Pubitemid 38198189)
4. Eknoyan G, Levin A, Levin N. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1-201.
5. Ganrot PO. Metabolism and possible health effects of aluminum. Environ Health Perspect 1986; 65:363-441. (Pubitemid 16117505)
6. Greger JL, Sutherland JE. Aluminum exposure and metabolism. Crit Rev Clin Lab Sci 1997; 34:439-474. (Pubitemid 27514230)
7. Lin JL, Leu ML. Aluminium-containing agents may be toxic in predialysis chronic renal insuffi ciency patients. J Intern Med 1996; 240:243-248.
8. Boeckmann AJ, Beal SL, Sheiner LB. NONMEM VI Users Guides. Technical Report. In: Pharmacology DoC, ed. San Francisco, CA: University of California; 2006.
9. Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analy sis: application to midazolam. J Pharmacokinet Biopharm 1991; 19: 377-384.
10. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based populationpharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58:51-64. (Pubitemid 29049052)
11. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic - pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20:511-528. (Pubitemid 23034413)
12. Mayor GH, Burnatowska-Hledin M. The metabolism of aluminum and aluminum-related encephalopathy. Semin Nephrol 1986; 6:1-4.
13. Hodsman AB, Steer BM. Serum aluminum levels as a refl ection of renal osteodystrophy status and bone surface aluminum staining. J Am Soc Nephrol 1992; 2:1318-1327.
14. Priest ND, Newton D, Day JP, Talbot RJ, Warner AJ. Human metabolism of aluminium-26 and gallium-67 injected as citrates. Hum Exp Toxicol 1995; 14:287-293.
15. Montenegro J, Aguirre R, Saracho R, Moina I, Martinez I. Factors infl uencing serum aluminum in CAPD patients. Clin Nephrol 1998; 50:77-83. (Pubitemid 28400998)
16. Rottembourg J, Gallego JL, Jaudon MC, Clavel JP, Legrain M. Serum concentration and peritoneal transfer of aluminum during treatment by continuous ambulatory peritoneal dialysis. Kidney Int 1984; 25:919-924. (Pubitemid 14050287)
17. Salusky IB, Coburn JW, Paunier L, Sherrard DJ, Fine RN. Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis. J Pediatr 1984; 105:717-720. (Pubitemid 15206697)
18. Burwen DR, Olsen SM, Bland LA, Arduino MJ, Reid MH, Jarvis WR. Epidemic aluminum intoxication in hemodialysis patients traced to use of an aluminum pump. Kidney Int 1995; 8: 469-474.
19. Mion C. Aluminium in continuous ambulatory peritoneal dialysis and post dilutional hemofi ltration. Clin Nephrol 1985; 24:S88-93. (Pubitemid 16188166)
20. Fifi eld LK, Day JO, Oldham CL, Carling R. Study of the kinetics of aluminium absorption and excretion in humans. Department of Nuclear Physics, Annual Report 1997: Australian National University, Canberra; 1997: 97-101.
21. Krewski D, Yokel RA, Nieboer E, Borchelt D, Cohen J, Harry J, et al. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B Crit Rev 2007; 10:1-269.
22. Wilhelm M, Passlick J, Busch T, Ohnesorge FK. Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. J Toxicol Clin Toxicol 1988; 26:209-221.
23. Joffe P, Olsen F, Heaf JG, Gammelgaard B, Podenphant J. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1989; 32:133-138. (Pubitemid 19228227)
24. McCarthy JT, Kurtz SB, Mussman GV. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis. Am J Med 1987; 82:367-370.
25. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. In: Society SP, ed. 4th ed. Stockholm: Swedish Pharmaceutical Press; 2006: 19-20.
26. van Landeghem GF, de Broe ME, D'Haese PC. Al and Si: their speciation, distribution, and toxicity. Clin Biochem 1998; 31: 385-397.
27. Priest ND. The bioavailability and metabolism of aluminium compounds in man. Proc Nutr Soc 1993; 52:231-240.
28. Nayak P. Aluminum: impacts and disease. Environ Res 2002; 89: 101-115. (Pubitemid 34680879)
29. Ljunggren KG, Lidums V, Sjogren B. Blood and urine concentrations of aluminium among workers exposed to aluminium fl ake powders. Br J Ind Med 1991; 48:106-109.